Market Cap 61.24M
Revenue (ttm) 0.00
Net Income (ttm) -12.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 55,900
Avg Vol 12,076
Day's Range N/A - N/A
Shares Out 5.10M
Stochastic %K 62%
Beta 0.49
Analysts Strong Sell
Price Target $39.00

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilima...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 994 8250
Address:
149 Fifth Avenue, Suite 500, New York, United States
OrientBeach
OrientBeach Sep. 14 at 7:27 PM
$INKT With another high volume trading day today … shorts are exiting in droves News must be on the horizon
0 · Reply
OrientBeach
OrientBeach Sep. 14 at 7:01 PM
$INKT Well, well, well, look what I found! A private company made a substanial investment in INKT acquiring 464.0K shares post split in May ’24 https://investor.minktherapeutics.com/static-files/3a649952-959b-4d1a-9cc3-cbfa36d76914 No wonder the daily trading volume is so low. The float has been absorbed
1 · Reply
enkemm
enkemm Sep. 14 at 5:08 PM
$INKT Here is the insiders breakdown: Major Individual Insider Holdings: Garo H. Armen (Founder & Chairman of the Board): Holds the largest position among individual insiders, controlling a significant direct and indirect portion of the remaining insider pool (~4.3% to 6.6% of the company's total outstanding common stock historically). Jennifer S. Buell (President & CEO): 57,942 shares Brian Corvese (Independent Director): 53,137 shares John Baldoni (Insider/Director): 41,193 shares Barbara Ryan (Independent Director): 21,969 shares Other Board Members & Executives (including Peter Behner, Ulf Wiinberg, and John Holcomb): Hold smaller fractional amounts that balance out the rest of the 857,394 share total.
1 · Reply
enkemm
enkemm Sep. 14 at 2:26 PM
$INKT I believe it is a bit more than 51% ownership. Mink insiders own about 16.8% of Mink's 5.1M shares (857,394 shares). Agenus holds about 42.7% (2,177,286 shares). So...about 59.5% of Mink's 5.1M shares are owned by what I consider insiders. Now...perhaps I am wrong, but AI gave me this info.
1 · Reply
OrientBeach
OrientBeach Sep. 14 at 2:00 PM
$INKT Shorts have covered ~35.0K shares in the last six weeks. Considering insiders own 51.0% it could be they are doing so because they are seeing the data https://fintel.io/ss/us/inkt
0 · Reply
svertical1
svertical1 Sep. 11 at 3:30 PM
$INKT Article below is pertinent to NK Cells as well. Both IBRX & INKT are positioned well for the Paradigm change to Immunotherapy! Long overdue. Imagine, any of us could be critically ill with Cancer, Pneumonia/Sepsis with known treatments that work. FDA…your turn.
0 · Reply
Dancady1
Dancady1 Sep. 10 at 8:29 PM
$INKT chart looks good. Some news and volume would be nice
1 · Reply
weichsel1
weichsel1 Sep. 10 at 2:17 PM
$INKT Any news explaining the jump up today?
0 · Reply
kellyc09
kellyc09 Sep. 9 at 5:49 PM
$INKT I remember this stock being $70 not long ago. Took a flyer a few months back so will see if it ever moves hard again.
0 · Reply
svertical1
svertical1 Sep. 9 at 4:01 PM
$INKT Big question, do they have an ARDS drug, or not. Unmet needs see quicker approvals.
0 · Reply
Latest News on INKT
MiNK Therapeutics Earnings Call Transcript: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 4 weeks ago

MiNK Therapeutics Earnings Call Transcript: Q2 2026


MiNK Therapeutics Earnings release: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 4 weeks ago

MiNK Therapeutics Earnings release: Q2 2026


MiNK Therapeutics Quarterly report: Q2 2026

Aug 13, 2026, 8:30 AM EDT - 4 weeks ago

MiNK Therapeutics Quarterly report: Q2 2026


MiNK Therapeutics Transcript: AGM 2026

Jun 17, 2026, 9:30 AM EDT - 2 months ago

MiNK Therapeutics Transcript: AGM 2026


MiNK Therapeutics doses first patient in agenT-797 trial

2026-05-28T14:12:03.000Z - 3 months ago

MiNK Therapeutics doses first patient in agenT-797 trial


MiNK Therapeutics reports new data on agenT-797 at ATS 2026

2026-05-20T15:15:48.000Z - 3 months ago

MiNK Therapeutics reports new data on agenT-797 at ATS 2026


MiNK Therapeutics Earnings Call Transcript: Q1 2026

May 15, 2026, 8:30 AM EDT - 4 months ago

MiNK Therapeutics Earnings Call Transcript: Q1 2026


MiNK Therapeutics Earnings release: Q1 2026

May 15, 2026, 8:30 AM EDT - 4 months ago

MiNK Therapeutics Earnings release: Q1 2026


MiNK Therapeutics Quarterly report: Q1 2026

May 15, 2026, 8:30 AM EDT - 4 months ago

MiNK Therapeutics Quarterly report: Q1 2026


MiNK Therapeutics initiates agenT-797 clinical trial

2026-05-14T17:31:11.000Z - 4 months ago

MiNK Therapeutics initiates agenT-797 clinical trial


MiNK Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

MiNK Therapeutics Proxy statement: Proxy filing


MiNK Therapeutics management to meet virtually with B. Riley

2026-04-20T17:05:20.000Z - 4 months ago

MiNK Therapeutics management to meet virtually with B. Riley


MiNK Therapeutics Earnings Call Transcript: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 5 months ago

MiNK Therapeutics Earnings Call Transcript: Q4 2025


MiNK Therapeutics Annual report: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 5 months ago

MiNK Therapeutics Annual report: Q4 2025


MiNK Therapeutics Earnings release: Q4 2025

Mar 31, 2026, 8:30 AM EDT - 5 months ago

MiNK Therapeutics Earnings release: Q4 2025


3 Penny Stocks to Watch Now, 3/11/26

2026-03-11T14:11:00.000Z - 6 months ago

3 Penny Stocks to Watch Now, 3/11/26

ATPC LGVN


Why Is MiNK Therapeutics Stock (INKT) Up Today?

2026-03-10T12:33:59.000Z - 6 months ago

Why Is MiNK Therapeutics Stock (INKT) Up Today?


MiNK Therapeutics Registration statement: Registration Filing

Dec 10, 2025, 7:00 AM EST - 9 months ago

MiNK Therapeutics Registration statement: Registration Filing


MiNK Therapeutics Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

MiNK Therapeutics Earnings Call Transcript: Q3 2025


MiNK Therapeutics Quarterly report: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

MiNK Therapeutics Quarterly report: Q3 2025


MiNK Therapeutics Earnings release: Q3 2025

Nov 14, 2025, 8:30 AM EST - 10 months ago

MiNK Therapeutics Earnings release: Q3 2025


MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year

2025-11-14T12:35:56.000Z - 10 months ago

MiNK Therapeutics reports Q3 EPS (65c) vs (46c) last year


MiNK Therapeutics files $150M mixed securities shelf

2025-11-07T22:00:18.000Z - 10 months ago

MiNK Therapeutics files $150M mixed securities shelf


MiNK Therapeutics reports updated clinical results on agenT-797

2025-11-07T14:05:54.000Z - 10 months ago

MiNK Therapeutics reports updated clinical results on agenT-797


MiNK Therapeutics Registration statement: Registration Filing

Nov 7, 2025, 7:00 AM EST - 10 months ago

MiNK Therapeutics Registration statement: Registration Filing


MiNK Therapeutics appoints John Holcomb to board of directors

2025-09-29T11:45:50.000Z - 11 months ago

MiNK Therapeutics appoints John Holcomb to board of directors


MiNK Therapeutics Earnings Call Transcript: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q2 2025


MiNK Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q2 2025


MiNK Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q2 2025


MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year

2025-08-14T11:40:29.000Z - 1 year ago

MiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last year


MiNK Therapeutics Earnings Call Transcript: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q1 2025


MiNK Therapeutics Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Quarterly report: Q1 2025


MiNK Therapeutics Earnings release: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q1 2025


MiNK Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Earnings Call Transcript: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q4 2024


MiNK Therapeutics Annual report: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Annual report: Q4 2024


MiNK Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 8:30 AM EDT - 1 year ago

MiNK Therapeutics Earnings release: Q4 2024


MiNK Therapeutics Proxy statement: Proxy Filing

Dec 20, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Proxy statement: Proxy Filing

Dec 6, 2024, 7:00 AM EST - 1 year ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings Call Transcript: Q3 2024


MiNK Therapeutics Quarterly report: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Quarterly report: Q3 2024


MiNK Therapeutics Earnings release: Q3 2024

Nov 14, 2024, 8:30 AM EST - 1 year ago

MiNK Therapeutics Earnings release: Q3 2024


MiNK Therapeutics Earnings Call Transcript: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q2 2024


MiNK Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q2 2024


MiNK Therapeutics Earnings release: Q2 2024

Aug 13, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q2 2024


MiNK Therapeutics Registration statement: Registration Filing

Aug 13, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Registration statement: Registration Filing


MiNK Reports Second Quarter 2024 Results and Business Update

Aug 13, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Second Quarter 2024 Results and Business Update


MiNK Therapeutics Earnings Call Transcript: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q1 2024


MiNK Therapeutics Quarterly report: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Quarterly report: Q1 2024


MiNK Therapeutics Earnings release: Q1 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q1 2024


MiNK Reports First Quarter 2024 Results

May 14, 2024, 7:30 AM EDT - 2 years ago

MiNK Reports First Quarter 2024 Results


MiNK Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Proxy statement: Proxy Filing


MiNK Therapeutics Earnings Call Transcript: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings Call Transcript: Q4 2023


MiNK Therapeutics Annual report: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Annual report: Q4 2023


MiNK Therapeutics Earnings release: Q4 2023

Mar 21, 2024, 8:30 AM EDT - 2 years ago

MiNK Therapeutics Earnings release: Q4 2023


MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 21, 2024, 7:00 AM EDT - 2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results


OrientBeach
OrientBeach Sep. 14 at 7:27 PM
$INKT With another high volume trading day today … shorts are exiting in droves News must be on the horizon
0 · Reply
OrientBeach
OrientBeach Sep. 14 at 7:01 PM
$INKT Well, well, well, look what I found! A private company made a substanial investment in INKT acquiring 464.0K shares post split in May ’24 https://investor.minktherapeutics.com/static-files/3a649952-959b-4d1a-9cc3-cbfa36d76914 No wonder the daily trading volume is so low. The float has been absorbed
1 · Reply
enkemm
enkemm Sep. 14 at 5:08 PM
$INKT Here is the insiders breakdown: Major Individual Insider Holdings: Garo H. Armen (Founder & Chairman of the Board): Holds the largest position among individual insiders, controlling a significant direct and indirect portion of the remaining insider pool (~4.3% to 6.6% of the company's total outstanding common stock historically). Jennifer S. Buell (President & CEO): 57,942 shares Brian Corvese (Independent Director): 53,137 shares John Baldoni (Insider/Director): 41,193 shares Barbara Ryan (Independent Director): 21,969 shares Other Board Members & Executives (including Peter Behner, Ulf Wiinberg, and John Holcomb): Hold smaller fractional amounts that balance out the rest of the 857,394 share total.
1 · Reply
enkemm
enkemm Sep. 14 at 2:26 PM
$INKT I believe it is a bit more than 51% ownership. Mink insiders own about 16.8% of Mink's 5.1M shares (857,394 shares). Agenus holds about 42.7% (2,177,286 shares). So...about 59.5% of Mink's 5.1M shares are owned by what I consider insiders. Now...perhaps I am wrong, but AI gave me this info.
1 · Reply
OrientBeach
OrientBeach Sep. 14 at 2:00 PM
$INKT Shorts have covered ~35.0K shares in the last six weeks. Considering insiders own 51.0% it could be they are doing so because they are seeing the data https://fintel.io/ss/us/inkt
0 · Reply
svertical1
svertical1 Sep. 11 at 3:30 PM
$INKT Article below is pertinent to NK Cells as well. Both IBRX & INKT are positioned well for the Paradigm change to Immunotherapy! Long overdue. Imagine, any of us could be critically ill with Cancer, Pneumonia/Sepsis with known treatments that work. FDA…your turn.
0 · Reply
Dancady1
Dancady1 Sep. 10 at 8:29 PM
$INKT chart looks good. Some news and volume would be nice
1 · Reply
weichsel1
weichsel1 Sep. 10 at 2:17 PM
$INKT Any news explaining the jump up today?
0 · Reply
kellyc09
kellyc09 Sep. 9 at 5:49 PM
$INKT I remember this stock being $70 not long ago. Took a flyer a few months back so will see if it ever moves hard again.
0 · Reply
svertical1
svertical1 Sep. 9 at 4:01 PM
$INKT Big question, do they have an ARDS drug, or not. Unmet needs see quicker approvals.
0 · Reply
2_logs_higher
2_logs_higher Sep. 9 at 4:27 AM
$AGEN & $INKT: giggles Jen presenting, but no one from AGENUS.
0 · Reply
svertical1
svertical1 Sep. 5 at 7:04 PM
$INKT It’s fairly normal to hear screams of ‘dilution’ on Stoktwits when following small Biotech, but just know…a legit ARDS drug is a $BILLION+ seller out the gate!
2 · Reply
svertical1
svertical1 Sep. 5 at 3:58 PM
$INKT Regardless, a $59M market cap for a stock that could very soon have an approved treatment for ARDS is an insanely low valuation. Patient Trials for ARDS are quick, drug works or it doesn’t. Early results suggests T-797 + Anktiva works. https://investor.minktherapeutics.com/news-releases/news-release-details/mink-therapeutics-reports-new-data-agent-797-allo-inkt-cell/
0 · Reply
svertical1
svertical1 Sep. 5 at 3:50 PM
$INKT I thought there was a combo Trial planned (for late this year) with ImmunityBio’s Anktiva in both Critically Ill Pneumonia with and without Sepsis, but I think ImmunityBio either was dropped or backed out. Appears both Companies are proceeding alone. Anyone know the back story?
1 · Reply
svertical1
svertical1 Sep. 5 at 3:44 PM
$INKT A very different mode of action…so perhaps synergistic but not really a competitor. Fostamatinib - blocks the activity of the enzyme spleen tyrosine kinase (SYK). By blocking SYK's activity, fostamatinib reduces the immune system's destruction of platelets, so allowing the platelet count to rise, which reduces the likelihood of excessive bleeding
0 · Reply
OrientBeach
OrientBeach Sep. 1 at 1:55 PM
$INKT We will soon have a new competitor in the quest for an ARDS therapeutic https://ctv.veeva.com/study/fostamatinib-for-treating-acute-respiratory-distress-syndrome-ards-in-hospitalized-adults Trail was schedule to start August 30, 2026
1 · Reply
svertical1
svertical1 Aug. 31 at 9:40 PM
$INKT Great info….
0 · Reply
svertical1
svertical1 Aug. 31 at 3:06 PM
$INKT Agree, but isn’t their plan to transition Phase 2 to Phase 3 based on positive P2 results?
1 · Reply
VintageCulture
VintageCulture Aug. 29 at 4:40 AM
Watch NCRA 1000% runner potential, 0 shares to short 500% CTB $13 fair value MASSIVE MICRON TIES one of the most undervalued setups you will find $TROO $LCFY $INKT $ENLV 😏❤️❤️😏❤️
1 · Reply
Spartrap
Spartrap Aug. 28 at 1:49 PM
$INKT I'm switching this from the low conviction stack to the medium conviction stack. I like the patent that I found. Flimsy IP was my number #1 concern. I think they have a neat and quick shot on goal in the ARDS setting with reasonable POS. Nobody is seeing it yet so it's time to buy. GL.
2 · Reply
Spartrap
Spartrap Aug. 27 at 1:58 PM
$INKT this company might have a dusty two years old corporate deck, but it has this: NCT07615010 Don't sleep on it. It's hot AF
1 · Reply
Spartrap
Spartrap Aug. 27 at 1:45 PM
$INKT with good P2 data in early 27, this could go to $105-125. I'd expect the SP to touch between a quarter and a third of that before results, depending on what transpires
0 · Reply